In the renal anemia market, Nephrologists seem to be settling into the new treatment standards (e.g., lower target hemoglobin levels, lower levels for ESA initiation, holds, and dose reductions) and more than two-thirds do not anticipate making any additional changes to their use of ESAs in CKD or dialysis. While Amgen's Epogen continues to dominate the dialysis market, there did seem to be some brand shifting between Amgen's Aranesp and Ortho Biotech's Procrit in CKD. Nephrologists do not predict significant changes in ESA market share in CKD or dialysis in the near-term, but they do project that bundling will have an impact on ESA use most likely through shifts to subcutaneous dosing and less aggressive treatment of EPO hypo-responders. New ESAs in development could also shift market dynamics particularly if these products are able to meet what Nephrologists identified as the most desired attributes in a new ESA.
In terms of IV iron, American Regent's Venofer remains the market
leader in both dialysis and CKD, however, office-based Nephrologists report
significantly higher CKD share for Venofer and hospital-based Nephrologists
report significantly higher CKD share for Watson's Ferrlecit. In the
dialysis market, very little brand switching took place in the past year,
although 60% of Nephrologists primarily affiliated with Fresenius units
expect their use of Venofer to increase following the news that Fresenius
will be marketing and distributing Venofer in dialysis units. Awareness of
AMAG Pharmaceutical's Ferumoxytol continues to be low. Among those famil
|SOURCE BioTrends Research Group, Inc.|
Copyright©2008 PR Newswire.
All rights reserved